CircSETD2 inhibits YAP1 by interaction with HuR during breast cancer progression

References

• Akram M, Iqbal M, Daniyal M, Khan AU. Awareness and current knowledge of breast cancer. Biol Res. 2017;50(1):33. doi:10.1186/s40659-017-0140-9.
   PubMed Web of Science ®Google Scholar
• Coutino-Escamilla L, Pina-Pozas M, Tobias Garces A, Gamboa-Loira B, López-Carrillo L. Non-pharmacological therapies for depressive symptoms in breast cancer patients: Systematic review and meta-analysis of randomized clinical trials. Breast. 2019;44:135–11. doi:10.1016/j.breast.2019.01.006.
   PubMed Web of Science ®Google Scholar
• McDonald ES, Clark AS, Tchou J, Zhang P, Freedman GM. Clinical diagnosis and management of breast cancer. J Nucl Med. 2016;57(Suppl 1):9S–16S. doi:10.2967/jnumed.115.157834.
   PubMed Web of Science ®Google Scholar
• Tang J, Ahmad A, Sarkar FH. MicroRNAs in breast cancer therapy. Curr Pharm Des. 2014;20(33):5268–5274. doi:10.2174/1381612820666140128205239.
   PubMed Web of Science ®Google Scholar
• Aristizabal-Pachon AF, Takahashi CS. Effect of genetics, epigenetics and variations in the transcriptional expression of cadherin–E in breast cancer susceptibility. Biomedica. 2016;36(4):593–602. doi:10.7705/biomedica.v36i4.3135.
   PubMed Web of Science ®Google Scholar
• Lei B, Tian Z, Fan W, Ni, B. Circular RNA: a novel biomarker and therapeutic target for human cancers. Int J Med Sci. 2019;16(2):292–301. doi:10.7150/ijms.28047.
   PubMed Web of Science ®Google Scholar
• Bao L, Wang M, Fan Q. Hsa_circ_NOTCH3 regulates ZNF146 through sponge adsorption of miR-875-5p to promote tumorigenesis of hepatocellular carcinoma. J Gastrointest Oncol. 2021;12(5):2388–2402. doi:10.21037/jgo-21-567.
   PubMed Web of Science ®Google Scholar
• Qi L, Sun B, Yang B, Lu S. circRNA RPPH1 facilitates the aggravation of breast cancer development by regulating miR-542-3p/ARHGAP1 pathway. Cancer Biother Radiopharm. 2021;37(8):708–719. doi:10.1089/cbr.2020.4381.
   PubMedGoogle Scholar
• Xu JZ, Shao CC, Wang XJ, Zhao X, Chen J-Q, Ouyang Y-X, Feng J, Zhang F, Huang W-H, Ying Q, et al. circTada2as suppress breast cancer progression and metastasis by targeting miR-203a-3p/SOCS3 axis. Cell Death Disease. 2019;10(3):175. doi:10.1038/s41419-019-1382-y.
   PubMed Web of Science ®Google Scholar
• Liu M, Luo C, Dong J, Guo J, Luo Q, Ye C, Guo Z. CircRNA_103809 suppresses the proliferation and metastasis of breast cancer cells by sponging MicroRNA-532-3p (miR-532-3p). Front Genet. 2020;11:485. doi:10.3389/fgene.2020.00485.
   PubMed Web of Science ®Google Scholar
• Mrena J, Wiksten JP, Kokkola A, Nordling S, Ristimäki A, Haglund C. COX-2 is associated with proliferation and apoptosis markers and serves as an independent prognostic factor in gastric cancer. Tumour Biol. 2010;31(1):1–7. doi:10.1007/s13277-009-0001-4.
   PubMedGoogle Scholar
• Saunus JM, French JD, Edwards SL, Beveridge DJ, Hatchell EC, Wagner SA, Stein SR, Davidson A, Simpson KJ, Francis GD, et al. Posttranscriptional regulation of the breast cancer susceptibility gene BRCA1 by the RNA binding protein HuR. Cancer Res. 2008;68(22):9469–9478. doi:10.1158/0008-5472.CAN-08-1159.
   PubMed Web of Science ®Google Scholar
• Cho NH, Kang S, Hong S, An HJ, Choi YH, Jeong GB, Choi HK. Elevation of cyclin B1, active cdc2, and HuR in cervical neoplasia with human papillomavirus type 18 infection. Cancer Lett. 2006;232(2):170–178. doi:10.1016/j.canlet.2005.02.026.
   PubMed Web of Science ®Google Scholar
• Mrena J, Wiksten JP, Kokkola A, Nordling S, Haglund C, Ristimäki A. Prognostic significance of cyclin an in gastric cancer. Int J Cancer. 2006;119(8):1897–1901. doi:10.1002/ijc.21944.
   PubMed Web of Science ®Google Scholar
• Yu X, Li Y, Ding Y, Zhang H, Ding N, Lu M. HuR promotes Ovarian cancer cell proliferation by regulating TIMM44 mRNA stability. Cell Biochem Biophys. 2020;78(4):447–453. doi:10.1007/s12013-020-00939-w.
   PubMed Web of Science ®Google Scholar
• Hu YP, Jin YP, Wu XS, Yang Y, Li Y-S, Li H-F, Xiang S-S, Song X-L, Jiang L, Zhang Y-J, et al. LncRNA-HGBC stabilized by HuR promotes gallbladder cancer progression by regulating miR-502-3p/SET/AKT axis. Mol Cancer. 2019;18(1):167. doi:10.1186/s12943-019-1097-9.
   PubMed Web of Science ®Google Scholar
• Zanconato F, Battilana G, Cordenonsi M, Piccolo S. YAP/TAZ as therapeutic targets in cancer. Curr Opin Pharmacol. 2016;29:26–33. doi:10.1016/j.coph.2016.05.002.
   PubMed Web of Science ®Google Scholar
• Xu W, Chen C, Xu R, Li Y, Hu R, Li Z, Zhu X. Knockdown of HuR represses osteosarcoma cells migration, invasion and stemness through inhibition of YAP activation and increases susceptibility to chemotherapeutic agents. Biomed Pharmacother. 2018;102:587–593. doi:10.1016/j.biopha.2018.03.098.
   PubMed Web of Science ®Google Scholar
• Ruan H, Xiang Y, Ko J, Li S, Jing Y, Zhu X, Ye Y, Zhang Z, Mills T, Feng J, et al. Comprehensive characterization of circular RNAs in ~ 1000 human cancer cell lines. Genome Med. 2019;11(1):55. doi:10.1186/s13073-019-0663-5.
   PubMed Web of Science ®Google Scholar
• Sanger HL, Klotz G, Riesner D, Gross HJ, Kleinschmidt AK. Viroids are single-stranded covalently closed circular RNA molecules existing as highly base-paired rod-like structures. Proc Natl Acad Sci U S A. 1976;73(11):3852–3856. doi:10.1073/pnas.73.11.3852.
   PubMed Web of Science ®Google Scholar
• Rybak-Wolf A, Stottmeister C, Glazar P, Jens M, Pino N, Giusti S, Hanan M, Behm M, Bartok O, Ashwal-Fluss R, et al. Circular RNAs in the mammalian brain are highly abundant, conserved, and dynamically expressed. Mol Cell. 2015;58(5):870–885. doi:10.1016/j.molcel.2015.03.027.
   PubMed Web of Science ®Google Scholar
• Lu C, Shi X, Wang AY, Tao Y, Wang Z, Huang C, Qiao Y, Hu H, Liu L. RNA-Seq profiling of circular RNAs in human laryngeal squamous cell carcinomas. Mol Cancer. 2018;17(1):86. doi:10.1186/s12943-018-0833-x.
   PubMed Web of Science ®Google Scholar
• Asghari H, Lin YY, Xu Y, Haghshenas E, Collins CC, Hach F. CircMiner: accurate and rapid detection of circular RNA through splice-aware pseudoalignment scheme. Bioinformatics. 2020;36(12):3703–3711. doi:10.1093/bioinformatics/btaa232.
   PubMed Web of Science ®Google Scholar
• Zong L, Sun Q, Zhang H, Chen Z, Deng Y, Li D, Zhang L. Increased expression of circRNA_102231 in lung cancer and its clinical significance. Biomed Pharmacother. 2018;102:639–644. doi:10.1016/j.biopha.2018.03.084.
   PubMed Web of Science ®Google Scholar
• Xu H, Liu Y, Cheng P, Wang C, Liu Y, Zhou W, Xu Y, Ji G. CircRNA_0000392 promotes colorectal cancer progression through the miR-193a-5p/PIK3R3/AKT axis. J Exp Clin Cancer Res. 2020;39(1):283. doi:10.1186/s13046-020-01799-1.
   PubMed Web of Science ®Google Scholar
• Chen D, Ma W, Ke Z, Xie F. CircRNA hsa_circ_100395 regulates miR-1228/TCF21 pathway to inhibit lung cancer progression. Cell Cycle. 2018;17(16):2080–2090. doi:10.1080/15384101.2018.1515553.
   PubMed Web of Science ®Google Scholar
• Ren L, Li Y, Zhao Q, Fan L, Tan B, Zang A, Yang H. miR‑519 regulates the proliferation of breast cancer cells via targeting human antigen?R. Oncol Lett. 2020;19:1567–1576. doi:10.3892/ol.2019.11230.
   PubMed Web of Science ®Google Scholar
• Yuan Z, Sanders AJ, Ye L, Jiang WG. HuR, a key post-transcriptional regulator, and its implication in progression of breast cancer. Histol Histopathol. 2010;25(10):1331–1340. doi:10.14670/HH-25.1331.
   PubMed Web of Science ®Google Scholar
• Yang F, Hu A, Li D, Wang J, Guo Y, Liu Y, Li H, Chen Y, Wang X, Huang K, et al. Circ-HuR suppresses HuR expression and gastric cancer progression by inhibiting CNBP transactivation. Mol Cancer. 2019;18(1):158. doi:10.1186/s12943-019-1094-z.
   PubMed Web of Science ®Google Scholar
• Heinonen M, Fagerholm R, Aaltonen K, Kilpivaara O, Aittomäki K, Blomqvist C, Heikkilä P, Haglund C, Nevanlinna H, Ristimäki A, et al. Prognostic role of HuR in hereditary breast cancer. Clin Cancer Res. 2007;13(23):6959–6963. doi:10.1158/1078-0432.CCR-07-1432.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Yang L, Ling C, Heng W. HuR facilitates cancer stemness of lung cancer cells by regulating miR-873/CDK3 and miR-125a-3p/CDK3 axis. Biotechnol Lett. 2018;40(4):623–631. doi:10.1007/s10529-018-2512-9.
   PubMed Web of Science ®Google Scholar
• Liu Y, Chen X, Cheng R, Yang F, Yu M, Wang C, Cui S, Hong Y, Liang H, Liu M, et al. The Jun/miR-22/HuR regulatory axis contributes to tumorigenesis in colorectal cancer. Mol Cancer. 2018;17(1):11. doi:10.1186/s12943-017-0751-3.
   PubMedGoogle Scholar
• Liu H, Lan T, Li H, Xu L, Chen X, Liao H, Chen X, Du J, Cai Y, Wang J, et al. Circular RNA circDLC1 inhibits MMP1-mediated liver cancer progression via interaction with HuR. Theranostics. 2021;11(3):1396–1411. doi:10.7150/thno.53227.
   PubMed Web of Science ®Google Scholar
• Sun Z, Ou C, Liu J, Chen C, Zhou Q, Yang S, Li G, Wang G, Song J, Li Z, et al. RETRACTED ARTICLE: YAP1-induced MALAT1 promotes epithelial–mesenchymal transition and angiogenesis by sponging miR-126-5p in colorectal cancer. Oncogene. 2019;38(14):2627–2644. doi:10.1038/s41388-018-0628-y.
   PubMed Web of Science ®Google Scholar
• Simile MM, Latte G, Demartis MI, Brozzetti S, Calvisi DF, Porcu A, Feo CF, Seddaiu MA, Daino L, Berasain C, et al. Posttranslational deregulation of YAP1 is genetically controlled in rat liver cancer and determines the fate and stem-like behavior of the human disease. Oncotarget. 2016;7(31):49194–49216. doi:10.18632/oncotarget.10246.
   PubMedGoogle Scholar
• Li Z, Wang Y, Hu R, Xu R, Xu W. LncRNA B4GALT1-AS1 recruits HuR to promote osteosarcoma cells stemness and migration by enhancing YAP transcriptional activity. Cell Prolif. 2018;51(6):e12504. doi:10.1111/cpr.12504.
   PubMed Web of Science ®Google Scholar
• Vrbsky J, Vinarsky V, Perestrelo AR, De La Cruz JO, Martino F, Pompeiano A, Izzi V, Hlinomaz O, Rotrekl V, Sudol M, et al. Evidence for discrete modes of YAP1 signaling via mRNA splice isoforms in development and diseases. Genomics. 2021;113(3):1349–1365. doi:10.1016/j.ygeno.2021.03.009.
   PubMed Web of Science ®Google Scholar